⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Oncolytics Biotech: Turing Heads And Necks

Published 06/12/2014, 03:04 AM
Updated 07/09/2023, 06:31 AM

Turning heads and necks

Oncolytics Biotech Inc. (NASDAQ:ONCY) recently reported positive additional data from the restructured Phase II squamous cell carcinoma of the head and neck (SCCHN) [REO 018] study following censoring of the data for the key confounding factors resulting from an imperfect study design, which made the original data difficult to interpret. Positive preclinical results were also presented at the recent OV 2014, which suggested that Reolysin has potential benefit in additional cancer and anti-viral indications. Reolysin is in seven ongoing randomised Phase II trials, which are expected to deliver results in 2014.

Oncolytics Biotech Chart

Positive additional SCCHN data

Additional data from the restructured Phase II trial for 165 (of 167) SCCHN patients (REO 018) with loco-regional disease ± metastases showed that Reolysin achieved, over five cycles of therapy, a statistically significant improvement in progression-free survival (PFS) [p=0.0072] and overall survival (OS) [p=0.0146] after censoring patients for the key confounding factors, and a positive trend towards better tumour stabilisation (0% growth) or shrinkage. In the 47 patients with metastatic-only disease, eight were still alive by April. Reolysin maintained a PFS benefit for five cycles of therapy and there was statistically significant better tumour stabilisation or shrinkage (p=0.021).

Encouraging preclinical results at OV 2014

Positive preclinical results were presented at the recent Oncolytic Virus (OV) 2014 conference on Yes-Associated Protein (YAP-1) as a potential reovirus biomarker for SCCHN and the potential for reovirus to be used in the treatment of hepatitis B (HBV) and hepatitis C (HCV) ± hepatocellular carcinoma (HCC). Reolysin can also cross the human blood brain barrier and may be synergistic with granulocyte macrophage colony stimulating factor (GM-CSF) for treating a range of cancers.

Financials: Funded to H215

Oncolytics had cash of C$20.2m at 31 March 2014. In February 2014, the company entered into a share purchase agreement with Lincoln Park Capital Fund, LLC for an initial investment of US$1.0m and up to US$25.0m over 30 months.

Valuation: Risk-adjusted NPV of C$442m

We reduce our rNPV slightly to C$442m due to the implied delay in launching the lead product. By comparison, Oncolytics’s EV is C$108m, based on a market cap of C$128m and end-Q1 cash of C$20m.

To Read the Entire Report Please Click on the pdf File Below

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.